Pfizer COVID-19 vaccine offers six months of protection, clinical trial show

Pfizer/BioNTech said Thursday that the COVID-19 vaccine offers protection that lasts six months after the second dose, according to ongoing research for their Phase 3 clinical trial.  

The vaccine is 91% effective against disease with any symptoms for half a year and offers protection against the South African variant of the virus called B.1.351.  

“The vaccine was 100% effective against severe disease as defined by the U.S. Centers for Disease Control and Prevention (CDC), and 95.3% effective against severe COVID-19 as defined by the U.S. Food and Drug Administration (FDA),” Pfizer and BioNTech said in a statement to CNN.  

RELATED: Pfizer/BioNTech testing COVID-19 vaccine in children under 12 

The vaccine’s protection of six months is longer than previously thought, according to CNN.  

“The high vaccine efficacy observed through up to six months following a second dose and against the variant prevalent in South Africa provides further confidence in our vaccine’s overall effectiveness,” said Pfizer’s chairman and CEO, Albert Bourla.  

Over 44,000 adults are participating in the Phase 3 trials. The data is from 12,000 of those participants, according to Yahoo.  

The news comes after the companies revealed that the vaccine offers adequate protection for adolescents between 12 and 15 years old, BNC previously reported. 

Latest in News


Women Serving Life Sentences Without Parole Increased Over Past Decade


Group of Current and Former Black Women Cops Sue DC Police


Joyce Beatty Initiates Rosa Parks National Holiday


LGBTQ Veterans Discharged for Sexual Orientation to Receive VA Benefits


Search Continues for Jelani Day Who’s Been Missing Since August


George Holliday, Who Filmed Rodney King Beating, Dies From COVID-19

Denzel Washington


Denzel Washington Stars in ‘The Tragedy of Macbeth’


Couple Who Aimed Guns at BLM Protestors Facing Law License Suspension